While science labs at SFU’s Surrey campus have been devoid of the buzz of student experiments and discovery for nearly two months, they recently came to life for another purpose—the production of hand sanitizer to help the community battle COVID-19. A small group of staff and faculty, donning lab coats and gloves and practicing physical distancing, packaged more than 800 250-ml…
Read More
Over the past decade, researchers have been studying the human microbiome—an array of microorganisms including bacteria, parasites, viruses, and fungi—to determine how it might be involved in disease. When it comes to Parkinson’s Disease (PD), most research has focused on defining the PD microbiome and attempting to link these microorganisms to neurological systems. A study published this week in the journal…
Read More
Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has received ethics approval from the Royal Brisbane & Women’s Hospital, Human Research Ethics Committee for the Company’s planned Phase 2 Idiopathic Pulmonary fibrosis (IPF) and chronic cough clinical study of its re-purposed drug NP-120 (Ifenprodil), an NMDA…
Read More
An international research team has identified the mechanism behind one of science’s most enduring mysteries: what makes the 100-year-old tuberculosis (TB) vaccine so effective at preventing newborn deaths from diseases other than TB? The ability of Bacillus Calmette-Guérin (BCG)—one of the oldest, safest and cheapest vaccines available—to provide protection to newborns beyond its intended purpose of fighting off TB has…
Read More
ARTMS Products Inc. (ARTMS), a global leader in the development of novel technologies enabling the production of the world’s highest demand diagnostic imaging isotopes, and Telix Pharmaceuticals Limited (Telix), a clinical-stage biopharmaceutical company developing diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR) announced today they have entered into a development collaboration agreement to employ ARTMS’ high activity production of Gallium-68 (68Ga) for the…
Read More
InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (“CBN”), today announced it has received regulatory and ethics board approval of its Clinical Trial Application (“CTA”) to conduct its second Phase 1 trial with INM-755. The 755-102-HV clinical…
Read More
AbCellera announced today it has received a commitment of up to $175.6 million in support from the Government of Canada under Innovation, Science and Economic Development’s (ISED) Strategic Innovation Fund (SIF) to expand efforts related to the discovery of antibodies for use in drugs to treat COVID-19, and to build technology and manufacturing infrastructure for antibody therapies against future pandemic…
Read More
Does continuing research after the (academic) lab sound like the right career move? Industry labs work towards a specific goal or application that may seem to have a more immediate effect on society than basic research labs. If working in a fast-paced lab environment sounds interesting, then perhaps applied research at a biotech company may be the answer. Dr. Stefanie…
Read More
For the first time, UBC researchers have shown a key difference in the three-dimensional structures of a key metabolic enzyme in the parasite that causes malaria compared to its human counterpart. The finding, recently published in the International Union of Crystallography Journal, brings researchers one step closer to developing new therapies to combat drug-resistant malaria. The structural differences of the metabolic…
Read More